PDCD1 and neoplasm: Based on the negative regulatory effect of TIGIT on tumor immunity, currently, there are a variety of anti-TIGIT mAbs as monotherapy or combined with PD-1/PD-L1 antibody or combined with chemotherapy to treat tumors.